Cargando…

Upadacitinib for the treatment of psoriatic arthritis

Psoriatic arthritis is a chronic systemic inflammatory disease that presents with a variable clinical course and is typically associated with joint inflammation, together with cutaneous psoriasis. In recent decades, knowledge of the pathogenesis of psoriatic arthritis has advanced considerably and h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fonseca, Diogo, Nogueira, Miguel, Torres, Tiago
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioExcel Publishing Ltd 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983629/ https://www.ncbi.nlm.nih.gov/pubmed/36876156 http://dx.doi.org/10.7573/dic.2022-11-6

Ejemplares similares

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Nogueira, Miguel, et al.
Publicado: (2021)

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
por: Mease, Philip J, et al.
Publicado: (2021)

Lymph node and pulmonary tuberculosis during upadacitinib treatment in a psoriatic arthritis patient
por: Valor-Méndez, Larissa, et al.
Publicado: (2022)

Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis
por: Nash, Peter, et al.
Publicado: (2021)

MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
por: Charles-Schoeman, Christina, et al.
Publicado: (2023)

Upadacitinib for rheumatoid arthritis
Publicado: (2020)

Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far
por: Martins, Ana, et al.
Publicado: (2023)

The role of upadacitinib in the treatment of moderate-to-severe active rheumatoid arthritis
por: Avci, Ali Berkant, et al.
Publicado: (2021)

An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far
por: Oliveira, Daniel G, et al.
Publicado: (2021)

Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review
por: Sanmartí, Raimon, et al.
Publicado: (2023)

Lymphomatoid papulosis during upadacitinib treatment for rheumatoid arthritis
por: Iinuma, Shin, et al.
Publicado: (2022)

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
por: Burmester, Gerd R, et al.
Publicado: (2023)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
por: Biggioggero, Martina, et al.
Publicado: (2019)

Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies
por: Baraliakos, Xenofon, et al.
Publicado: (2023)

Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials
por: Muensterman, Elena, et al.
Publicado: (2021)

Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials
por: Burmester, Gerd R., et al.
Publicado: (2021)

Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding
por: Kurizky, Patricia Shu, et al.
Publicado: (2015)

Treatment guidelines in psoriatic arthritis
por: Ogdie, Alexis, et al.
Publicado: (2020)

Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials
por: McInnes, Iain B, et al.
Publicado: (2022)

Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study
por: McInnes, Iain B., et al.
Publicado: (2022)

Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication
por: Mohamed, Mohamed-Eslam F., et al.
Publicado: (2019)

Deucravacitinib for the Treatment of Psoriatic Disease
por: Lé, Ana Maria, et al.
Publicado: (2022)

The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan
por: Yamaoka, Kunihiro, et al.
Publicado: (2021)

Psoriatic arthritis
por: Ocampo D, Vanessa, et al.
Publicado: (2019)

Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice
por: Werner, Stephanie G., et al.
Publicado: (2023)

Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study
por: Luchetti Gentiloni, Michele Maria, et al.
Publicado: (2023)

Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
por: Strand, Vibeke, et al.
Publicado: (2021)

Infliximab (Remicade) in the treatment of psoriatic arthritis
por: Mease, Philip
Publicado: (2006)

Ustekinumab for the treatment of psoriatic arthritis: an update
por: Davari, Parastoo, et al.
Publicado: (2014)

Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2015)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
por: Harrington, Robert, et al.
Publicado: (2023)

Kaposi sarcoma in a patient treated with upadacitinib for rheumatoid arthritis
por: Fournier, Cynthia, et al.
Publicado: (2023)

Management of Axial Spondyloarthritis – Insights into Upadacitinib
por: Braun, Jürgen, et al.
Publicado: (2022)

Clinical potential of apremilast in the treatment of psoriatic arthritis
por: Cauli, Alberto, et al.
Publicado: (2014)

An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis
por: Chimenti, Maria Sole, et al.
Publicado: (2020)

Choosing the right treatment for patients with psoriatic arthritis
por: Noviani, Maria, et al.
Publicado: (2020)

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
por: McInnes, Iain B, et al.
Publicado: (2021)

Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study
por: Mease, Philip J., et al.
Publicado: (2021)

Psoriatic Arthritis: An Update
por: Lloyd, Peter, et al.
Publicado: (2012)

P36 Crohn’s-associated inflammatory arthritis treated successfully with upadacitinib
por: Carroll, James, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s6gmd3g6uvmv7mdae5v6jprep5